||Comparison of In vitro and In vivo Methods for Evaluating Alterations in Hepatic Drug Metabolism Following Mercuric Chloride Administration.
Trela, B. A. ;
Carlson, G. P. ;
Chadwick, R. W. ;
Copeland, M. F. ;
||Health Effects Research Lab., Research Triangle Park, NC. ;Purdue Univ., Lafayette, IN. School of Pharmacy and Pharmacal Sciences.
Mercuric chloride ;
Nephrotic syndrome ;
Mixed function oxidases
||Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy.
||Mercuric chloride was administered once ip to female Fischer 344 rats at doses of 0, 0.2, 0.6, and 1.8 mg/kg. Although there were no alterations in the urinary excretion of lactate dehydrogenase, significant elevations in the activities of urinary alkaline phosphatase, glutamicpyruvic transaminase and glutamicoxalacetic transaminase indicated that mercuric chloride was nephrotoxic. There was no evidence of hepatotoxicity as hepatic glucose-6-phosphatase and serum sorbitol dehydrogenase were essentially unaffected by mercuric chloride administration. Of the four phase II reactions measured, only the glucuronidation of chloramphenicol was diminished by treatment with mercuric chloride. Results from the in vivo studies on the metabolism of lindane, which indicated no change in the excretion of free or conjugated metabolites, were in close agreement with the in vitro data suggesting that the nephrotoxic effects of mercuric chloride do not alter the urinary excretion of the model substrate lindane.
||Pub. in Toxicology Letters, v32 p133-140 1986. Prepared in cooperation with Purdue Univ., Lafayette, IN. School of Pharmacy and Pharmacal Sciences.
|NTIS Title Notes
||Reprint: Comparison of In vitro and In vivo Methods for Evaluating Alterations in Hepatic Drug Metabolism Following Mercuric Chloride Administration.
|PUB Date Free Form
||57B; 57O; 57Y
||PC A02/MF A01